New pill shows promise for arthritis patients who fail standard treatments
NCT ID NCT07452445
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 4 trial tests ivarmacitinib, a once-daily pill, in 100 adults with moderate-to-severe rheumatoid arthritis who did not improve on standard drugs. The study will measure joint symptom improvement after 12 weeks and monitor safety. Ivarmacitinib works by blocking inflammation signals and has shown high response rates in earlier studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivarmacitinib (a JAK1 inhibitor drug taken as a pill once daily)
- What this could lead to
- If successful, this could provide a new second-line treatment option for rheumatoid arthritis patients who do not respond to standard first-line therapies.
- What could go wrong
- This is a Phase 4 study with only 100 participants, so results may not apply to all patients. Common side effects include infections, anemia, and high cholesterol.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?